An observational study in Acute Ischemic Stroke, sponsored by Shanghai Jiao Tong University Affiliated Sixth People's Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by Shanghai Jiao Tong University Affiliated Sixth People's Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 753 studies in Ischemic Stroke with a site in China — 380 open to participants now, 399 under way, 78 of them phase 3. Ischemic Stroke · China.
Among the 753 studies in Ischemic Stroke with a site in China, this one is the 134th largest by planned enrollment of the 188 observational ones that give a count, is one of 103 that started in 2024, is one of 188 observational ones, reaches primary completion later than 328 of the 398 other live ones, and was the 737th registered.
2,625 studies on the registry are indexed under Ischemic Stroke; 982 are open to participants now.
Browse Ischemic Stroke studies →380 of the 753 studies in Ischemic Stroke with a site in China are open now. Recruiting first, the newest first:
Xidian University · Sites in China
Ages 18+
The First Affiliated Hospital of Zhengzhou University · Sites in China
Ages 18+
Shanghai Jiao Tong University Affiliated Sixth People's Hospital · Sites in China
Ages 18–85
Yongjun Wang · Sites in China
Ages 18+
Shandong Provincial Hospital · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 668 Ischemic Stroke studies recruiting now, 402 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
753 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 42 · Phase 2 110 · Phase 3 136 · Phase 4 70
First in 2000; this study’s year is marked. 103 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is below the median of 300 across 775 observational studies indexed under Ischemic Stroke.
Median enrollment 270 across the 565 interventional studies, 625 across the 188 observational. Of the 235 that completed or were terminated, 10 (4%) have results posted.
This tab as a report to print or save as PDF → With an account.
80 of 753 have an industry lead sponsor. The 10 most frequent:
Shanghai Jiao Tong University Affiliated Sixth People's Hospital is the lead sponsor of 41 studies on the registry; 23 are open to participants now.
Shanghai Jiao Tong University Affiliated Sixth People's Hospital has 7 studies filed under Ischemic Stroke — fewer than ten, so there is no comparison to draw.
109 of the studies in Ischemic Stroke with a site in China that are under way reach primary completion within a year, 23 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06559241Phase 3Capital Medical UniversityRemote Ischemic Conditioning for Acute Ischemic Stroke Treated With Mechanical Thrombectomy(RECAST-MT) | 2026-11 |
| NCT06615726Phase 3Capital Medical UniversityRegular Physical Exercise in Patients With Symptomatic Intracranial Arterial Stenosis | 2026-11-19 |
| NCT06658197Phase 3Xuanwu Hospital, BeijingEfficacy and Safety of Tenecteplase Bridging Mechanical Thrombectomy for Acute Large Vessel Occlusion Stroke | 2026-12-01 |
| NCT06749834Phase 3Second Affiliated Hospital, School of Medicine, Zhejiang UniversityIntravenous Thrombolysis and NOAC | 2026-12-31 |
| NCT07335107Phase 3Beijing Tiantan HospitalIntravenous Tirofiban After Bridging Therapy for Acute Stroke With Atherosclerotic Large Artery Occlusion | 2027-01-31 |
Add all 109 to your calendar (.ics) → With an account.
Among the 753 studies in Ischemic Stroke with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This prospective observational cohort study aims to investigate the association between magnetic resonance spectroscopy (MRS) parameters and early neurological deterioration (END) in patients with large vessel occluded acute ischemic stroke. Eligible patients will undergo MRS examination during the acute phase of stroke after entry into hospital, and relevant clinical, imaging, and laboratory data will be prospectively collected. Participants will then be followed to determine the occurrence of END and prognosis during the predefined observation period. The study will evaluate whether MRS-derived metabolic parameters are associated with the risk of END and explore their potential predictive value for early neurological deterioration after acute ischemic stroke.
LVO-AIS(Large vessel occluded acute ischemic stroke) within 24 hours of onset (NIHSS\< 6 points)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Magnetic resonance spectroscopy performed during the acute phase of ischemic stroke to assess cerebral metabolic characteristics.
Number of participants with early neurologic deterioration
Early neurologic deterioration due to ischemia within 3 days after enrollment (an increase of ≥4 points compared to baseline NIHSS, excluding non-ischemic causes such as hemorrhage and epilepsy)
Time frame: within 3 days after enrollment
Modified rankin scale
The modified Rankin Scale (mRS) is a 7-point global disability scale with scores ranging from 0 (no symptoms) to 6 (death); higher scores indicate a worse functional outcome. The mRS will be assessed at 3 months and categorized as good functional outcome (modified Rankin Scale score 0-2; range 0-6, higher scores indicate worse outcome) versus poor functional outcome (modified Rankin Scale score 3-6; range 0-6, higher scores indicate worse outcome).
Time frame: 3-month after enrollment
Mini-Mental state examination for cognitive evaluation
The Mini-Mental State Examination (MMSE) is a brief, 30-point cognitive screening instrument that assesses orientation, registration, attention and calculation, recall, language, and visuospatial/constructional ability. Scores range from 0 to 30, and higher scores indicate better cognitive function (lower scores indicate greater cognitive impairment). Cutoffs vary by version and educational level; commonly, a score of ≤23 or ≤24 suggests cognitive impairment, and education-adjusted thresholds may be used.
Time frame: 3 month after enrollment
Dynamic changes in relative N-acetylaspartate over time
Relative N-acetylaspartate change dynamically over time and space from the acute phase (within 24 hours), subacute phase (3-5 days), to the chronic phase (3 months).
Time frame: Acute phase (within 24 hours), subacute phase (3-5 days), to the chronic phase (3 months).
Montreal cognitive assessment for cognitive evaluation
The Montreal Cognitive Assessment (MoCA) is a brief cognitive screening instrument that assesses executive function, naming, memory, attention, language, abstraction, delayed recall, and orientation. Scores range from 0 to 30, and higher scores indicate better cognitive function (lower scores indicate greater cognitive impairment). A commonly used cutoff is \<26 for detecting cognitive impairment, though education- and population-specific thresholds may be more appropriate; the original version adds 1 point for ≤12 years of education.
Time frame: 3 month after enrollment
Dynamic changes in relative lactate over time
Relative lactate change dynamically over time and space from the acute phase (within 24 hours), subacute phase (3-5 days), to the chronic phase (3 months).
Time frame: Acute phase (within 24 hours), subacute phase (3-5 days), to the chronic phase (3 months).
Dynamic changes in relative choline over time
Relative choline change dynamically over time and space from the acute phase (within 24 hours), subacute phase (3-5 days), to the chronic phase (3 months).
Time frame: Acute phase (within 24 hours), subacute phase (3-5 days), to the chronic phase (3 months).
Changes in lactate/N-acetylaspartate over time
Lactate/N-acetylaspartate change dynamically over time and space from the acute phase (within 24 hours), subacute phase (3-5 days), to the chronic phase (3 months).
Time frame: Acute phase (within 24 hours), subacute phase (3-5 days), to the chronic phase (3 months).
Plan to share: Undecided
Started Aug 2024 (actual). Primary completion is estimated for Dec 2028, 52 months after the start.
Of 400 non-industry observational studies under Ischemic Stroke, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 140. This study's planned 52 months is close to that.
Counting every sponsor, half of 442 studies reached it within 54 months; a quarter within 24 and three quarters within 127.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Shanghai Jiao Tong University Affiliated Sixth People's Hospital